A novel compound which sensitizes BRAF wild-type melanoma cells to vemurafenib in a TRIM16-dependent manner
Supplementary
: TRIM16 is reactivated with combination C012 and vemurafenib in BRAF wildtype, but not mutant cells. (A) Mel-JD, Mel-RM, MM200 and A375 cells lines were assessed at 72 hours of treatment of DMSO control, C012 at 4 μM, vemurafenib (VEM) at 5 μM, or combination (C012 +VEM) by western blotting for molecular changes in ERK and MEK phosphorylation for activity assessment of the MAPK pathway. TRIM16 protein expression was also assessed. GAPDH was used as a loading control. (B) Immunoblotting was performed for ERK phosphorylation and TRIM16 protein expression with GAPDH is used as a loading control in normal fibroblast line, MRC-5. 

